Posted on

Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization

General Track – Cycle 1 | Vaccines

HTA Council Recommendation (as of 16 May 2025)

The HTA Council positively recommends the government financing of the following PCVs for infants less than 1 year old and children aged 13 to 23 months, in no particular order:

  • Pneumococcal Polysaccharide And Non-Typeable Haemophilus Influenzae (Nthi) Protein D Conjugate Vaccine, Adsorbed [PCV10-GSK]
  • Pneumococcal Polysaccharide Conjugate Vaccine. (Adsorbed) (10-valent) [PCV10-SII]
  • Pneumococcal Conjugate Vaccine, 13-Valent [PCV13] 
  • Pneumococcal Polysaccharide Conjugate Vaccine, 15 Valent (Adsorbed) [PCV15]

Recommending the above-mentioned vaccines will provide the National Immunization Program (NIP) more options and more flexibility in the selection of the most suitable PCV. This will allow the NIP to select a PCV that can address changes in the prevalent serotypes in the country through time. This also ensures that the selection aligns with the available budget and resources of DOH and takes into account other programmatic and implementation considerations. In addition, this recommendation allows further competition to drive down the cost of PCVs.

Relevant Information

  • Status: with Final HTA Council Recommendation
  • Topic Assignment: External Assessment
  • Policy Question: Should Pneumococcal Conjugate Vaccine (PCV) for Infants less than 1 year old and children aged 13 to 23 months for catch-up immunization be funded by the government?
  • Secretary of Health Decision:  Approved for inclusion in the Philippine National Formulary

Evidence and Relevant Documents

Assessment History

Back to Assessments Page